lab-in-the-loop
(3)
Antiverse
Antiverse is a UK-based AI-driven biotech that designs functional therapeutic antibodies against targets long considered 'undruggable' - notably G-protein coupled receptors (GPCRs), ion channels, and other transmembrane proteins where conventional antibody discovery routinely fails. Its platform pairs generative AI models, trained for years on the hardest antibody targets, with a proprietary 'lab-in-the-loop' wet lab using engineered cell lines and deep sequencing, taking a target to an optimized antibody in roughly four months. Founded in 2017 and headquartered in Cardiff, Wales, the company works through pharma partnerships and licensing (e.g. Nxera Pharma) alongside its own internal pipeline and non-profit collaborations such as the Cystic Fibrosis Foundation.
Fathom Therapeutics
Fathom Therapeutics (formerly Atommap) is a New York and Boston based biotech building Microcosmos, a drug-design engine that fuses quantum chemistry and AI to simulate how proteins actually move inside living cells. By modeling motion instead of static snapshots - reportedly up to 10,000x faster than conventional simulation - the company hunts for the fleeting binding pockets that make 'undruggable' targets druggable, then designs small molecules, degraders, and molecular glues against them. In April 2026 it raised a $47M oversubscribed Series A led by Sutter Hill Ventures.
Huafeng Xu
Huafeng Xu is the founder and CEO of Fathom Therapeutics (formerly AtomMap), a New York drug-design company that simulates protein motion at atomic resolution to design small molecules that work inside living cells. A computational chemist with 25+ years and 10,000+ citations, Xu spent 12 years at D. E. Shaw Research building the free-energy and molecular-dynamics methods now standard across pharma, then served as CTO of Silicon Therapeutics and Roivant Discovery before launching his own company. In April 2026 Fathom closed an oversubscribed $47M Series A led by Sutter Hill Ventures to scale its Microcosmos engine.